Literature DB >> 22108844

Persistency of Pseudomonas aeruginosa in sputum cultures and clinical outcomes in adult patients with cystic fibrosis.

A Burkett1, K L Vandemheen, T Giesbrecht-Lewis, K Ramotar, W Ferris, F Chan, S Doucette, D Fergusson, S D Aaron.   

Abstract

Our objective was to describe the natural history of infection with transmissible and unique strains of P. aeruginosa (PA) in adult CF patients and to determine if clearance of PA from sputum was associated with an improvement in clinical status. This was a 3-year prospective cohort study of adult patients with CF. Sputum was collected at baseline and annually. Rate of decline of FEV1, BMI, exacerbation rate, and time to death or transplant were compared between patients who cleared PA versus those in whom PA was persistent. A total of 373 patients were included in the study, 75% were infected with PA at baseline; 24% were infected with transmissible strains and 51% with unique strains. Patients infected with unique strains were more likely to clear PA from their sputum over 3 years compared to those infected with transmissible strains (19% vs 10%, P=0.05). Declines in FEV1 and rates of pulmonary exacerbations, deaths, or lung transplants were not different between patients who cleared PA compared to those who remained persistently infected. No clinical benefit was identified in patients who cleared PA from sputum compared to those who remained persistently infected.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22108844     DOI: 10.1007/s10096-011-1483-8

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  19 in total

1.  Prevalence and persistence of polyagglutinable Pseudomonas aeruginosa in isolates from cystic fibrosis patients.

Authors:  B Ojeniyi; N Høiby; V T Rosdahl
Journal:  APMIS       Date:  1991-02       Impact factor: 3.205

2.  Determinants of mortality from cystic fibrosis in Canada, 1970-1989.

Authors:  M Corey; V Farewell
Journal:  Am J Epidemiol       Date:  1996-05-15       Impact factor: 4.897

3.  Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.

Authors:  G Taccetti; S Campana; F Festini; M Mascherini; G Döring
Journal:  Eur Respir J       Date:  2005-09       Impact factor: 16.671

4.  Characterization of clonal strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Ontario, Canada.

Authors:  Trevor Beaudoin; Shawn D Aaron; Tracy Giesbrecht-Lewis; Kathy Vandemheen; Thien-Fah Mah
Journal:  Can J Microbiol       Date:  2010-07       Impact factor: 2.419

5.  Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling.

Authors:  Geraint B Rogers; Stuart Skelton; David J Serisier; Christopher J van der Gast; Kenneth D Bruce
Journal:  J Clin Microbiol       Date:  2009-11-11       Impact factor: 5.948

Review 6.  Pathophysiology and management of pulmonary infections in cystic fibrosis.

Authors:  Ronald L Gibson; Jane L Burns; Bonnie W Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2003-10-15       Impact factor: 21.405

7.  Reference spirometric values using techniques and equipment that meet ATS recommendations.

Authors:  R O Crapo; A H Morris; R M Gardner
Journal:  Am Rev Respir Dis       Date:  1981-06

8.  Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis.

Authors:  S D Aaron; D Kottachchi; W J Ferris; K L Vandemheen; M L St Denis; A Plouffe; S P Doucette; R Saginur; F T Chan; K Ramotar
Journal:  Eur Respir J       Date:  2004-10       Impact factor: 16.671

9.  Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.

Authors:  K Cheng; R L Smyth; J R Govan; C Doherty; C Winstanley; N Denning; D P Heaf; H van Saene; C A Hart
Journal:  Lancet       Date:  1996-09-07       Impact factor: 79.321

10.  Epidemiological investigation and glycotyping of clinical Pseudomonas aeruginosa isolates from patients with cystic fibrosis by mass spectrometry: association with multiple drug resistance.

Authors:  Eleonora Altman; Zhan Wang; Shawn D Aaron; Xin Liu; Katherine L Vandemheen; Wendy Ferris; Tracy Giesbrecht; Jianjun Li
Journal:  J Microbiol Methods       Date:  2008-10-28       Impact factor: 2.363

View more
  9 in total

1.  N-3-(oxododecanoyl)-L-homoserine lactone promotes the induction of regulatory T-cells by preventing human dendritic cell maturation.

Authors:  Youqiang Li; Huayou Zhou; Yunyan Zhang; Cha Chen; Bin Huang; Pinghua Qu; Jianming Zeng; E Shunmei; Xuan Zhang; Jianping Liu
Journal:  Exp Biol Med (Maywood)       Date:  2015-03-06

Review 2.  Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.

Authors:  Michael D Parkins; Ranjani Somayaji; Valerie J Waters
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

3.  Cystic Fibrosis Lung Transplant Recipients Have Suppressed Airway Interferon Responses during Pseudomonas Infection.

Authors:  Daniel T Dugger; Monica Fung; Lorna Zlock; Saharai Caldera; Louis Sharp; Steven R Hays; Jonathan P Singer; Lorriana E Leard; Jefferey A Golden; Rupal J Shah; Jasleen Kukreja; Erin Gordon; Walter Finkbeiner; Mary Ellen Kleinhenz; Chaz Langelier; John R Greenland
Journal:  Cell Rep Med       Date:  2020-07-21

Review 4.  Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review.

Authors:  M C Gaspar; W Couet; J-C Olivier; A A C C Pais; J J S Sousa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-26       Impact factor: 3.267

5.  Editorial Commentary: Pseudomonas aeruginosa Eradication: How Do We Measure Success?

Authors:  Edith T Zemanick; Theresa A Laguna
Journal:  Clin Infect Dis       Date:  2015-05-13       Impact factor: 9.079

6.  Changes of Proteases, Antiproteases, and Pathogens in Cystic Fibrosis Patients' Upper and Lower Airways after IV-Antibiotic Therapy.

Authors:  Ulrike Müller; Julia Hentschel; Wibke K Janhsen; Kerstin Hünniger; Uta-Christina Hipler; Jürgen Sonnemann; Wolfgang Pfister; Klas Böer; Thomas Lehmann; Jochen G Mainz
Journal:  Mediators Inflamm       Date:  2015-06-21       Impact factor: 4.711

7.  The lung microbiome in children with HIV-bronchiectasis: a cross-sectional pilot study.

Authors:  Refiloe Masekela; Solize Vosloo; Stephanus N Venter; Wilhelm Z de Beer; Robin J Green
Journal:  BMC Pulm Med       Date:  2018-05-22       Impact factor: 3.317

8.  Lung Microbiota Changes Associated with Chronic Pseudomonas aeruginosa Lung Infection and the Impact of Intravenous Colistimethate Sodium.

Authors:  David Collie; Laura Glendinning; John Govan; Steven Wright; Elisabeth Thornton; Peter Tennant; Catherine Doherty; Gerry McLachlan
Journal:  PLoS One       Date:  2015-11-06       Impact factor: 3.240

9.  Reduced neutrophil elastase inhibitor elafin and elevated transforming growth factor-β1 are linked to inflammatory response in sputum of cystic fibrosis patients with Pseudomonas aeruginosa.

Authors:  Jan C Thomassen; Tobias Trojan; Maxine Walz; Christina Vohlen; Gregor Fink; Ernst Rietschel; Miguel A Alejandre Alcazar; Silke van Koningsbruggen-Rietschel
Journal:  ERJ Open Res       Date:  2021-07-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.